Stockpolly
Search
Delisting risk
MTNB · AMEX · Biotechnology

Matinas BioPharma (MTNB)

Developer of lipid nanocrystal delivery technology for oral antifungal treatment.

$0.1865
Pre-market−0.00 (−1.69%)
At close$0.1897(−4.05%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue40322000000
Gross profit−40−3−2−2000000
26226221222
Research & development43322000000
22222221222
Selling & marketing00000000000
General & administrative22222221222
Other expenses−40−3−22000000
Operating income−6−6−6−4−8−2−2−2−2−2−2
100000−3−1000
Other non-operating income−1000−4031−100
Income before tax−5−6−6−4−9−2−5−2−2−2−1
Income tax expense00000000000
Net income from continuing operations−5−6−6−4−8−2−5−2−2−2−1
Net income−5−6−6−4−8−2−5−2−2−2−1
EPS, basic−$1.22−$1.34−$1.15−$0.85−$1.73−$0.33−$1.03−$0.40−$0.30−$0.30−$0.21
EPS, diluted−$1.22−$1.34−$1.15−$0.85−$1.73−$0.33−$1.03−$0.40−$0.30−$0.30−$0.21
Weighted average shares, basic44555555566
Weighted average shares, diluted44555555566
EBITDA−5−6−6−4−4−2−5−2−1−2−2
Depreciation & amortization00000000000
EBIT−5−6−6−4−4−2−5−2−1−2−2